NuVasive, Inc. (NASDAQ:NUVA) Given Average Recommendation of "Hold" by Brokerages
NuVasive, Inc. (NASDAQ:NUVA) Given Average Recommendation of "Hold" by Brokerages
Shares of NuVasive, Inc. (NASDAQ:NUVA – Get Rating) have received a consensus rating of "Hold" from the fifteen brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $61.75.
據MarketBeat報道,NuVasive,Inc.(納斯達克代碼:NuVA-GET評級)的股票已獲得目前覆蓋該公司的15家券商的共識評級為持有。一名分析師對該股的評級為賣出,六名分析師給出了持有評級,六名分析師給出了該公司的買入評級。在過去一年對該股進行評級的分析師中,平均一年目標價為61.75美元。
Several equities analysts recently weighed in on the stock. Morgan Stanley decreased their target price on shares of NuVasive from $62.00 to $54.00 and set an "equal weight" rating for the company in a research note on Friday, July 15th. Canaccord Genuity Group raised their target price on shares of NuVasive from $50.00 to $55.00 in a research note on Friday, August 5th. Piper Sandler decreased their target price on shares of NuVasive from $80.00 to $60.00 and set an "overweight" rating for the company in a research note on Thursday, August 4th. Finally, Truist Financial decreased their target price on shares of NuVasive to $63.00 in a research note on Friday, July 22nd.
幾位股票分析師最近對該股進行了加碼。摩根士丹利在7月15日星期五的一份研究報告中將NuVasive的股票目標價從62.00美元下調至54.00美元,併為該公司設定了“同等權重”的評級。在8月5日星期五的一份研究報告中,Canaccel Genuity Group將NuVasive的股票目標價從50.00美元上調至55.00美元。派珀·桑德勒在8月4日週四的一份研究報告中將NuVasive的股票目標價從80.00美元下調至60.00美元,併為該公司設定了“增持”評級。最後,Truist Financial在7月22日星期五的一份研究報告中將NuVasive的股票目標價下調至63.00美元。
NuVasive Price Performance
新的性價比
NASDAQ NUVA opened at $44.44 on Thursday. The company has a quick ratio of 0.70, a current ratio of 1.17 and a debt-to-equity ratio of 0.54. NuVasive has a 12-month low of $41.33 and a 12-month high of $63.46. The company has a market capitalization of $2.31 billion, a PE ratio of -55.55, a price-to-earnings-growth ratio of 1.72 and a beta of 1.18. The firm's 50 day moving average is $48.22 and its 200-day moving average is $51.35.
納斯達克Nuva週四開盤價為44.44美元。該公司的速動比率為0.70,流動比率為1.17,債務權益比率為0.54。NuVasive的12個月低點為41.33美元,12個月高位為63.46美元。該公司市值23.1億美元,市盈率為-55.55,市盈率為1.72,貝塔係數為1.18。該公司的50日移動均線切入位在48.22美元,200日移動均線切入位在51.35美元。
Institutional Investors Weigh In On NuVasive
機構投資者買入NuVasive股票
A number of hedge funds and other institutional investors have recently modified their holdings of NUVA. Victory Capital Management Inc. lifted its holdings in shares of NuVasive by 1,364.3% during the second quarter. Victory Capital Management Inc. now owns 648,236 shares of the medical device company's stock worth $31,868,000 after buying an additional 603,967 shares in the last quarter. Polar Asset Management Partners Inc. acquired a new position in NuVasive in the first quarter valued at about $27,627,000. Nuance Investments LLC acquired a new position in NuVasive in the first quarter valued at about $22,099,000. Woodline Partners LP raised its stake in NuVasive by 102.6% in the second quarter. Woodline Partners LP now owns 665,010 shares of the medical device company's stock valued at $32,692,000 after purchasing an additional 336,741 shares in the last quarter. Finally, Thrivent Financial for Lutherans raised its stake in NuVasive by 11.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 2,147,399 shares of the medical device company's stock valued at $112,696,000 after purchasing an additional 219,982 shares in the last quarter.
一些對衝基金和其他機構投資者最近修改了對Nuva的持股。勝利資本管理公司在第二季度增持了1,364.3%的NuVasive股票。勝利資本管理公司現在持有這家醫療設備公司648,236股股票,價值31,868,000美元,上個季度又購買了603,967股。Polal Asset Management Partners Inc.在第一季度收購了NuVasive的一個新頭寸,價值約為27,627,000美元。Nuance Investments LLC在第一季度收購了NuVasive的一個新頭寸,價值約為22,099,000美元。Woodline Partners LP在第二季度將其在NuVasive的持股比例提高了102.6。Woodline Partners LP現在擁有這家醫療設備公司665,010股股票,價值32,692,000美元,上個季度又購買了336,741股。最後,Thrient Financial for Lutherans在第四季度將其在NuVasive的持股比例提高了11.4%。ThriventFinancial for Lutherans現在擁有這家醫療設備公司2147,399股股票,價值112,696,000美元,上個季度又購買了219,982股。
About NuVasive
關於NuVasive
(Get Rating)
(獲取評級)
NuVasive, Inc, a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment.
NuVasive,Inc.是一家醫療技術公司,開發、製造和銷售脊柱手術的程序解決方案。它提供手術准入器械,包括Maxcess集成的分刀式牽引器系統,該系統可以在脊柱手術中最大限度地減少軟組織破壞,從而實現較小的侵入性手術技術;專門的脊柱植入物,通過增強植入材料的骨整合和生物力學性能來促進脊柱融合,包括多孔鈦和多孔聚醚酮;以及有助於保存和恢復患者對齊狀態的固定系統。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on NuVasive (NUVA)
- This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
- A Trio of Q3 Winners With Room to Run
- Can HCA Healthcare Weather the Normalization?
- Can United Natural Foods Fight Both Inflation and the Fed?
- Mullen Automotive Is Ready To Get In Gear
- 免費獲取StockNews.com關於NuVasive(Nuva)的研究報告
- 這個小知名的小盤股上漲了139%:這隻股票是買入的嗎?
- 第三季度贏家三人組還有運行的空間
- HCA醫療能否經受住正常化的考驗?
- 聯合天然食品能同時對抗通脹和美聯儲嗎?
- 馬倫汽車已做好準備投入使用
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.
接受NuVasive Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對NuVasive和相關公司的最新新聞和分析師評級的每日簡要摘要。